锰-PyC3A的正电子发射断层-磁共振成像药代动力学、体内生物分布及全身消除
本研究用同步PET-MRI比较了实验性锰对比剂Mn-PyC3A与肝特异性对比剂锰福地吡在正常及5/6肾切除大鼠中的全身药代动力学、生物分布和消除,并比较了Mn-PyC3A与钆特酸在肾损伤模型中的消除。结果显示Mn-PyC3A经肾脏和肝胆混合消除,在肾损伤大鼠中肝胆排泄分数增加,且7天后从肾损伤大鼠体内消除比钆特酸更完全。
要点
- Mn-PyC3A经肾脏和肝胆双途径消除,正常大鼠中肾脏滤过占较大比例。
- 5/6肾切除大鼠中Mn-PyC3A肝胆排泄分数增加,膀胱AUC0-60降低而肝脏AUC0-60升高。
- 注射7天后Mn-PyC3A从5/6肾切除大鼠体内残留低于钆特酸。
核心结论
- Mn-PyC3A在正常大鼠中的药代动力学与锰福地吡不同,且消除更高效。
- Mn-PyC3A在正常和5/6肾切除大鼠中均能被有效消除,5/6肾切除大鼠中肝胆排泄分数增加。
- 注射7天后,Mn-PyC3A从5/6肾切除大鼠体内的消除比钆特酸更完全。
研究设计与样本
- 实验性锰基细胞外液MRI对比剂Mn-PyC3A的临床前研究,采用同步PET-MRI及离体伽马计数或钆元素分析。
- Mn-PyC3A和锰福地吡经52MnCl2与Mn2+交换进行52Mn放射性标记。
- 正常大鼠或5/6肾切除大鼠静脉注射0.2 mmol/kg [52Mn]Mn-PyC3A;正常大鼠注射0.01 mmol/kg [52Mn]Mn-DPDP;动态PET-MRI测量至注射后7天。
- 离体生物分布和分数排泄在大鼠注射2.0 mmol/kg [52Mn]Mn-PyC3A(每个时间点n=11)或2.0 mmol/kg Gd-DOTA(每个时间点n=8)后量化。
- 正常与5/6肾切除大鼠的药代动力学及体内生物分布比较,以及5/6肾切除大鼠离体锰与钆生物分布比较,采用非配对t检验。
关键影像表现/征象
- 动态PET-MRI显示[52Mn]Mn-PyC3A和[52Mn]Mn-DPDP均通过肾脏和肝胆混合途径消除,但[52Mn]Mn-PyC3A经肾脏滤过消除的比例更大。
- 全身PET图像显示[52Mn]Mn-PyC3A中的Mn-52被有效从体内消除,而[52Mn]Mn-DPDP中的Mn-52在全身滞留。
诊断标准与关键数值
- 正常大鼠与5/6肾切除大鼠中[52Mn]Mn-PyC3A的血液消除半衰期分别为13±3.5分钟和23±12分钟(P=0.083)。
- 正常大鼠与5/6肾切除大鼠膀胱AUC0-60分别为2600±1700 %ID/cc*min和750±180 %ID/cc*min(P=0.024)。
- 正常大鼠与5/6肾切除大鼠肝脏AUC0-60分别为33±13 %ID/cc*min和71±16 %ID/cc*min(P=0.011)。
- 注射后1天,5/6肾切除大鼠中[52Mn]Mn-PyC3A的锰%ID和Gd-DOTA的钆%ID分别为2.0±1.1和1.3±0.34(P=0.10)。
- 注射后7天,5/6肾切除大鼠中[52Mn]Mn-PyC3A的锰%ID和Gd-DOTA的钆%ID分别为0.14±0.11和0.41±0.24(P=0.0041)。
临床应用与阅片要点
- Mn-PyC3A作为实验性细胞外液MRI对比剂,在正常和5/6肾切除大鼠中均经肾脏和肝胆途径有效消除。
- 5/6肾切除大鼠中Mn-PyC3A肝胆排泄分数增加,提示肾损伤时肝胆途径代偿性排泄增强。
- 注射7天后Mn-PyC3A从5/6肾切除大鼠体内的残留低于钆特酸。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Mn-PyC3A is an experimental manganese (Mn)-based extracellular fluid magnetic resonance imaging (MRI) contrast agent that is being evaluated as a direct replacement for clinical gadolinium (Gd)-based contrast agents. The goals of this study were to use simultaneous positron emission tomography (PET)-MRI to (1) compare the whole-body pharmacokinetics, biodistribution, and elimination of Mn-PyC3A with the liver-specific contrast agent mangafodipir (Mn-DPDP), (2) determine the pharmacokinetics and fractional excretion of Mn-PyC3A in a rat model of renal impairment, and (3) compare whole-body elimination of Mn-PyC3A to gadoterate (Gd-DOTA) in a rat model of renal impairment.
METHODS: Mn-PyC3A and Mn-DPDP were radiolabeled with the positron emitting isotope Mn-52 via Mn2+ exchange with 52MnCl2. Dynamic simultaneous PET-MRI was used to measure whole-body pharmacokinetics and biodistribution of Mn-52 immediately and out to 7 days after an intravenous 0.2 mmol/kg dose of [52Mn]Mn-PyC3A to normal or to 5/6 nephrectomy rats or a 0.01 mmol/kg dose of [52Mn]Mn-DPDP to normal rats. The fractional excretion and 1- and 7-day biodistribution in rats after the injection of 2.0 mmol/kg [52Mn]Mn-PyC3A (n = 11 per time point) or 2.0 mmol/kg Gd-DOTA (n = 8 per time point) were quantified by gamma counting or Gd elemental analysis, respectively. Comparisons of Mn-PyC3A pharmacokinetics and in vivo biodistribution in normal and 5/6 nephrectomy rats and comparisons of ex vivo Mn versus Gd biodistribution data in 5/6 nephrectomy were made with an unpaired t test.
RESULTS: Dynamic PET-MRI data demonstrate that both [52Mn]Mn-PyC3A and [52Mn]Mn-DPDP were eliminated by mixed renal and hepatobiliary elimination but that a greater fraction of [52Mn]Mn-PyC3A was eliminated by renal filtration. Whole-body PET images show that Mn-52 from [52Mn]Mn-PyC3A was efficiently eliminated from the body, whereas Mn-52 from [52Mn]Mn-DPDP was retained throughout the body. The blood elimination half-life of [52Mn]Mn-PyC3A in normal and 5/6 nephrectomy rats was 13 ± 3.5 minutes and 23 ± 12 minutes, respectively (P = 0.083). Area under the curve between 0 and 60 minutes postinjection (AUC0-60) in the bladder of normal and 5/6 nephrectomy rats was 2600 ± 1700 %ID/cc*min and 750 ± 180 %ID/cc*min, respectively (P = 0.024), whereas AUC0-60 in the liver of normal and 5/6 nephrectomy rats was 33 ± 13 %ID/cc*min and 71 ± 16 %ID/cc*min, respectively (P = 0.011), indicating increased hepatobiliary elimination in 5/6 nephrectomy rats. The %IDs of Mn from [52Mn]Mn-PyC3A and Gd from Gd-DOTA recovered from 5/6 nephrectomy rats 1 day after injection were 2.0 ± 1.1 and 1.3 ± 0.34, respectively (P = 0.10) and 7 days after injection were 0.14 ± 0.11 and 0.41 ± 0.24, respectively (P = 0.0041).
CONCLUSIONS: Mn-PyC3A has different pharmacokinetics and is more efficiently eliminated than Mn-DPDP in normal rats. Mn-PyC3A is efficiently eliminated from both normal and 5/6 nephrectomy rats, with increased fractional hepatobiliary excretion from 5/6 nephrectomy rats. Mn-PyC3A is more completely eliminated than Gd-DOTA from 5/6 nephrectomy rats after 7 days.
引用
- Zhou IY, Ramsay IA, Ay I, et al. Positron Emission Tomography-Magnetic Resonance Imaging Pharmacokinetics, In Vivo Biodistribution, and Whole-Body Elimination of Mn-PyC3A. Invest Radiol. 2021. PMID: 33136686. doi:10.1097/RLI.0000000000000736
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。